The Centers for Disease Control and Prevention (CDC) has updated and revised its policy on “sensitive but unclassified” (SBU) information, the increasingly common twilight category of information that is neither classified nor publicly released.
“Marking information SBU does not automatically qualify it for a public release exemption,” the CDC policy observes. (There is no “SBU exemption” to the Freedom of Information Act.)
On the other hand, “the absence of the SBU or other related marking does not necessarily mean the information should be publicly released.”
“Therefore, all information should be reviewed and approved prior to its public release,” the CDC instructs.
A copy of the revised SBU policy was posted on the CDC intranet and obtained by Secrecy News.
The Government Accountability Office will publish a major report on the use of Sensitive But Unclassified control markings next month.
DNA synthesis and export controls remain the primary regulatory safeguards against de novo production of harmful biological agents, yet governance frameworks lack the situational awareness and enforcement capacity to keep pace with rapidly falling technical barriers.
Called today to speak on behalf of U.S. science and technology, Dr. Jedidah Isler, astrophysicist, educator, strategist, policy-maker, and science communicator, will provide constructive, nonpartisan feedback to the House Committee’s hearing “American Global Competitiveness at 250: Legislative Proposals to Secure U.S. Technology Leadership.”
“Federal data and access to it is not a partisan issue. It is a people issue. Our country cannot achieve greatness without access to the data that measure what we value, who we are, and where we’re heading.”
The United States’ biosecurity governance system is structurally incapable of detecting and responding to certain classes of threats. U.S. biosecurity tools have not kept pace with technological advancements or a changing threat landscape.